Contact the EpiPen4Schools Programs

Phone: 973-845-7600
Fax: 973-718-4328

BioRidge Pharma facilitates the certification and fulfillment
of the EpiPen4Schools® orders.
The EpiPen4Schools® program helps improve access to epinephrine in the event a person experiences a life-threatening allergic reaction (anaphylaxis) in the school setting.
The program offers qualifying schools*:
  • Four free EpiPen® (epinephrine injection, USP) or EpiPen Jr® (epinephrine injection, USP) Auto-Injectors in the form of two EpiPen 2-Pak® cartons, two EpiPen Jr 2-Pak® cartons or one 2-Pak of each kind.
    Note: schools may receive the authorized generic versions of EpiPen and EpiPen Jr
  • Free replenishment product in the event that the free supply is used to respond to a life-threatening allergic reaction.
  • How to Use an EpiPen® (epinephrine injection, USP) Auto-Injector, containing instructions on how to use Mylan epinephrine auto-injectors.
  • EpiPen® Trainers, which contain no drug product or needle, to practice administering EpiPen® Auto-Injector.
CLICK HERE to start your order.
An estimated one in 13 children in the U.S. lives with a food allergy that puts them at risk for anaphylaxis— a considerable increase from previous years. Though avoidance of allergic triggers is the only way to prevent anaphylaxis, the fact is that life happens and it’s possible for someone to experience an accidental exposure or first-time reaction.
Epinephrine is the only first-line treatment for anaphylaxis. According to the food allergy guidelines developed by the National Institute of Allergy and Infectious Diseases, if experiencing anaphylaxis, a person should receive an intramuscular injection of epinephrine and seek immediate emergency medical care. Carrying an epinephrine auto-injector does not prevent patients from having an anaphylactic reaction; hence, patients must avoid their triggers at all times.
For more information on anaphylaxis or EpiPen® Auto-Injectors, visit

Did you know?

Anaphylaxis can develop and progress quickly, and children and adolescents are among the most at risk. A survey of more than 8048 schools participating in EpiPen4Schools® revealed a total of 1,568 anaphylactic events among students and staff during the 2015-2016 school year. Also, the survey found:

  • More than one in four anaphylactic events occurred in the absence of an established or known allergic trigger
  • In 17% of reported anaphylaxis cases, the individual was not treated with epinephrine, the only first-line treatment for anaphylaxis
  • In those events where an epinephrine auto-injector was used, nearly 60% were treated with an EpiPen® Auto-Injector provided by the EpiPen4Schools® program
* A school will only receive epinephrine auto-injectors in accordance with all applicable laws. A school must submit a valid prescription in order to qualify for this program.